Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hepatitis C, Chronic 1Hepatitis C 1Fibrosis 1Diabetes Mellitus 1Cardiovascular Diseases 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 1270Specimen Handling 870Carboplatin 831Magnetic Resonance Spectroscopy 808Cyclophosphamide 802Cisplatin 728Nivolumab 658Paclitaxel 631Radiotherapy 573Gemcitabine 572Biopsy 529Bevacizumab 475Dexamethasone 440fludarabine 407Docetaxel 378venetoclax 370Oxaliplatin 365Capecitabine 356Fluorouracil 354atezolizumab 341durvalumab 334Rituximab 332Doxorubicin 316Radiosurgery 309Pemetrexed 305Drug Therapy 302Ipilimumab 294Standard of Care 293Etoposide 285Radiation 279

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × sofosbuvir-velpatasvir drug combination × 1 year × Clear all
NCT03520660 2026-06-03

People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

National Institutes of Health Clinical Center (CC)

Phase 4 Active not recruiting
121 enrolled
Gastrointestinal

Cardiovascular Diseases, Diabetes Mellitus, Fibrosis, Hepatitis C, Carcinoma, Hepatocellular, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡